Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Acquires 81,575 Shares of Company Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta purchased 81,575 shares of the company’s stock in a transaction dated Tuesday, November 17th. The stock was bought at an average price of $2.24 per share, with a total value of $182,728.00. Following the completion of the transaction, the director directly owned 376,359 shares of the company’s stock, valued at approximately $843,044.16. This represents a 27.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Eric Sachetta also recently made the following trade(s):

  • On Monday, August 31st, Eric Sachetta acquired 27,304 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.54 per share, for a total transaction of $96,656.16.
  • On Friday, August 28th, Eric Sachetta acquired 37,537 shares of Sensus Healthcare stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $129,127.28.
  • On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.18 per share, with a total value of $34,741.50.
  • On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.29 per share, with a total value of $31,939.32.
  • On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The stock was bought at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS traded up $0.18 during trading on Thursday, hitting $2.48. 69,188 shares of the company were exchanged, compared to its average volume of 105,719. The company has a fifty day moving average price of $2.93 and a 200-day moving average price of $3.41. The firm has a market capitalization of $40.75 million, a PE ratio of -2.56 and a beta of 1.18. Sensus Healthcare, Inc. has a 12-month low of $2.14 and a 12-month high of $5.49.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Sensus Healthcare had a negative net margin of 96.49% and a negative return on equity of 24.95%. The firm had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $6.61 million.

Analysts Set New Price Targets

SRTS has been the subject of a number of recent analyst reports. Lake Street Capital cut their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings cut Sensus Healthcare from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, November 13th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.83.

Read Our Latest Stock Report on Sensus Healthcare

Institutional Trading of Sensus Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers purchased a new stake in Sensus Healthcare in the third quarter valued at approximately $48,000. EP Wealth Advisors LLC purchased a new position in shares of Sensus Healthcare during the second quarter worth $49,000. Allworth Financial LP purchased a new position in shares of Sensus Healthcare during the third quarter worth $209,000. BlackRock Inc. acquired a new stake in shares of Sensus Healthcare in the second quarter valued at $252,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Sensus Healthcare in the second quarter valued at $303,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

(Get Free Report)

Sensus Healthcare, Inc. develops and markets medical devices for the treatment of non-melanoma skin cancer and other skin conditions. Its products use superficial radiation therapy, which delivers low-energy X-rays to targeted areas of the skin. The company’s product portfolio includes the SRT-100 platform and related systems designed for use in clinical settings. Sensus positions these technologies as non-invasive treatment options for conditions including basal and squamous cell skin cancers and keloids.

Recommended Stories

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.